Skip to content

Evaluation of new assays for the detection of TB

Evaluation of the performance, feasibility, acceptability and cost-effectiveness of new assays for the detection of tuberculosis: a multisite diagnostic accuracy study in Cameroon

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202502473140037
Enrollment
1200
Registered
2025-02-14
Start date
2025-02-17
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Interventions

Investigational diagnostic tests for TB

Sponsors

CHPR
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Aged =15 years People with presumptive TB, including: an abnormal chest X-ray OR cough >2 weeks OR any of W4SS (cough, fever, night sweats, weight loss) OR TB risk factor(s) including history of TB treatment, living with HIV, at risk of undernutrition, at risk of alcohol use disorders or use of tobacco Willing to provide the specimens needed for testing For those aged 15-20 years: a parent or guardian present at the time of enrolment to provide signed informed consent

Exclusion criteria

Exclusion criteria: Unwilling to provide informed consent (people aged 20 years and above) or unwilling to provide informed assent (15-20 years of age) Are currently on anti-TB treatment or who have taken anti-TB treatment within 60 days of enrollment Have taken tuberculosis preventive treatment (TPT) within 6 months of enrollment.

Design outcomes

Primary

MeasureTime frame
Point estimates, with 95% confidence interval, of the sensitivity and specificity of the new assays as compared to the defined reference standards

Secondary

MeasureTime frame
Difference between point estimates, with 95% confidence interval, of the sensitivity and specificity of the new molecular assays relative to sputum Ultra as comparator, using the microbiological reference standard ;Operational and implementation characteristics of assays;Perspectives and preferences of stakeholders;Cost-effectiveness using incremental cost-effectiveness ratio in natural units of cost per additional case detected

Countries

Cameroon

Contacts

Public ContactCyrille Mbuli

CHPR

cyrillembuli@gmail.com+237670793083

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026